New Central Licensing Rules for Stem Cell and Gene Therapies in India
Source:The Hindu ↗
Why It Matters
This development represents a critical structural reform in India's medical regulatory framework under the Drugs and Cosmetics Act. For the UPSC CSE, it is highly relevant for both GS Paper 3 (Science and Technology - Biotechnology applications) and GS Paper 2 (Governance - Health sector regulations). It showcases how the state is transitioning from a traditional generics-based drug approval system to an advanced bio-therapeutic framework to balance innovation with public safety.
Summary
The Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945, to bring stem cell therapies, gene editing products, and xenografts under the Centrally Licence Approving Authority (CLAA) framework. By establishing dedicated manufacturing licenses and joint Central-State regulatory oversight, this reform closes a critical legal loophole that allowed unproven clinic-level stem cell therapies to proliferate. While the move modernizes India's regulatory framework—shifting it away from a generic-drug paradigm to better evaluate novel therapies like CAR-T and CRISPR—it also introduces higher compliance costs and highlights persistent bottlenecks in clinical infrastructure and specialized workforce development.
Key Points
- The Union Ministry of Health and Family Welfare amended Rules 75, 75A, 76, and 76A of the Drugs Rules, 1945, to bring cell-based therapies, stem cell products, gene therapies, and xenografts under the Centrally Licence Approving Authority (CLAA) framework.
- The amendment bridges a long-standing regulatory gap where cell and stem cell products were classified as 'new drugs' since 2018 but lacked dedicated licensing forms (Forms 27D, 27DA, 28D, 28DA) for commercial manufacturing, letting clinics exploit the grey zone with unproven and costly stem cell treatments.
- The new framework covers regenerative medicine, CAR-T cell therapies (like India's first indigenous NexCAR19), CRISPR-based gene editing products (such as BIRSA-101 for sickle cell disease), and animal-tissue-derived products (xenografts) like cardiac heart valves.
- Historically, India’s drug regulatory architecture was designed around generic drugs and bioequivalence testing, making it ill-suited for advanced cell and gene therapies; previous approvals like NexCAR19 in 2023 had to be evaluated on an ad-hoc, case-by-case basis.
- While the dual oversight by Central and State authorities increases safety and uniform compliance, critics caution that the additional bureaucratic layer may prolong approval timelines and escalate development costs for niche, homegrown biotech startups.
Important Terms
Drugs and Cosmetics Act, 1940
A comprehensive pre-independence Indian legislation that regulates the import, manufacture, sale, and distribution of drugs, cosmetics, and medical devices to ensure their safety, quality, and efficacy.
UPSC context
GS Paper II (Governance & Health policies); tests the statutory framework governing pharmaceutical standards, public health, and drug safety in India.
Drugs Rules, 1945
Subordinate legislation framed under the Drugs and Cosmetics Act, 1940, detailing procedures for drug classification, licensing, packaging, and the operation of regulatory authorities in India.
UPSC context
GS Paper II (Delegated Legislation); tests knowledge of the administrative rules that govern pharmaceutical standards and clinical trial processes in India.
Centrally Licence Approving Authority (CLAA)
A joint regulatory mechanism under India's CDSCO that oversees and approves manufacturing licenses for high-risk, critical biological categories like vaccines, parenterals, and newly added advanced stem cell and gene therapies.
UPSC context
GS Paper II (Regulatory Bodies) & GS III (Biotechnology); tests regulatory mechanisms ensuring uniform safety and quality control for advanced medical technologies.
State Licensing Authorities
Decentralized state-level government bodies responsible for inspecting manufacturing facilities, issuing licenses, and monitoring the quality, distribution, and sale of drugs and cosmetics within their respective states.
UPSC context
GS Paper II (Federalism & Statutory Bodies); tests India's dual drug regulatory architecture involving cooperative federalism between Central and State drug control bodies.
Union Ministry of Health and Family Welfare
The central administrative ministry of India responsible for formulating national healthcare policies, medical education, public health programs, and regulating pharmaceutical standards and drug safety.
UPSC context
GS Paper II (Government Policies & Interventions); tests understanding of the nodal executive ministry driving national healthcare infrastructure and pharmaceutical safety.
Prelims Trap
Stem cell therapies were first classified as 'New Drugs' under Indian law by the 2026 amendment.
They were classified as New Drugs in 2018. The 2026 amendment specifically created the missing manufacturing licensing forms under the Drugs Rules, 1945.
Static Concepts Connected
How does the Centrally Licence Approving Authority (CLAA) operate?
- Constitutional base: It regulates drugs and cosmetics under Entry 19 of List III (Concurrent List), allowing both Central and State actions.
- Joint licensing: While the State Licensing Authority inspects, the final licensing approval authority rests with the Central Licence Approving Authority under CDSCO.
- Target categories: Historically limited to high-risk categories like vaccines, blood products, and large parenterals to ensure strict, uniform nationwide quality standards.
What is India's stance on germline vs somatic gene editing?
- Somatic editing: Editing of non-reproductive cells is allowed for therapeutic purposes, subject to clinical trials and CDSCO approval.
- Germline prohibition: Modifying reproductive cells (sperm, eggs, embryos) is legally and ethically prohibited to prevent inheritable genetic changes.
- Apex committees: Research projects must navigate the Institutional Ethics Committee (IEC) and the Review Committee on Genetic Manipulation (RCGM) under DBT.
Cross-Topic Patterns
Cooperative federalism in drug licensing
The joint Central-State CLAA framework resolves conflicts between Central standards (Concurrent List) and State-level health delivery (State List), ensuring uniform clinical safety.
Somatic therapy + Tribal health equity
Indigenous gene-editing (like BIRSA-101 for Sickle Cell Disease) links advanced biotechnology directly to public health objectives, such as the National Sickle Cell Elimination Mission.
Expect 2026 Prelims to test the joint CLAA mechanism, specifically distinguishing somatic cell therapies from banned germline editing.
Linked PYQs · 2
Linked PYQs · 2
- 2017MainsGS3
Stem cell therapy is gaining popularity in India to treat a wide variety of medical conditions including Leukaemia, Thalassemia, damaged cornea and severe burns. Describe briefly what stem cell therapy is and what advantages it has over other treatments?
- 2019PrelimsGS1
What is Cas9 protein that is often mentioned in news?
